Hidehito HORINOUCHI (@hhorinouchi.bsky.social)

🔥BREAKING🆙 ✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit 🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC 🎙️ @bms-news.bsky.social #LCSM @oncoalert.bsky.social news.bms.com/news/corpora...

loading . . .

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi... Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do... https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Opdivo-Plus-Chemotherapy-as-the-First-and-Only-Neoadjuvant-Only-Immuno-Oncology-Therapy-to-Demonstrate-Statistically-Significant-and-Clinically-Meaningful-Overall-Survival-in-Resectable-Non-Small-Cell-Lung-Cancer/default.aspx